Needham & Company
-
Notable Mergers and Acquisitions of the Day 08/26: (AMGN)/(ONXX) (APC) (GCOM) (TMS)
-
Stocks Showing 'Golden Cross' Pattern 06/21: (ABX) (ENDP) (FNSR) (CYTK)
-
Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal
-
Notable 52-Week Highs and Lows of the Day 12/21: (CTAS) (CVS) (AMGN) High; (AMGN) (VECO) (CREE) Low
-
Needham & Company on Watson Pharmaceuticals (WPI): Deal With Amgen Couples WPI’s Checkbook With Biotech Icon’s Development Prowess
-
Notable Analyst Rating Changes 11/22: (SIRI) (NVDA) (RIMM) Upgraded; (AMGN) (AFL) (DOLE) Downgraded
-
Needham & Company Reiterates a 'Buy' on Micromet (MITI); Signs BiTE Agreement with Another Brand Name Collaborator with Robust Terms
-
Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); Data from Phase 2 “Evidence of Effect” Trial in Claudication Confirm the Rapid Effect of CK-357
-
Needham & Company Maintains a 'Hold' on Cytokinetics (CYTK); CK-357 Data in ALS Encouraging, And We Await Study Findings in PVD and MG
-
Notable Analyst Rating Changes 01/04: WAG, AMGN, MON, WYNN Upgraded; NKE, SWY, SVU, PIP Downgraded
-
Notable Analyst Rating Changes 11/04: KIM, PHM, QCOM, HMA Upgraded; MPWR, PT, SWIR, K Downgraded
-
Notable Analyst Rating Changes 7/29: AMGN, AFL, DPS Upgraded; VNDA, ZRAN, SNDK Downgraded
-
Notable Analyst Rating Changes 7/28: AMGN, DKS, BBY, PCLN Upgraded; CLX, VSE, MPEL, HAS Downgraded

